“LORBRENA seen 48% year-over-year operational growth in the quarter, and we expect continued strength through 2025.”

In context

“outs for Padcev in muscle invasive bladder cancer in two ongoing studies. If successful and approved, we expect a significant expanded opportunity to treat patients with bladder cancer focused on the approximately 28,000 in the U.S. with MIBC, approximately 80% of whom undergo cystectomy. Cibinqo had strong 46% year-over-year operational growth with the quarter, driven by higher demand in the U.S. and growth in key international markets where we have decided to focus. We believe there is additional market opportunities for Cibinqo in responding to the need among patients with atopic dermatitis. We are seeing the clear impact of recent positive data released for several of our oncology products. It is contributing to strong growth in helping to establish these products as standard of care. LORBRENA seen 48% year-over-year operational growth in the quarter, and we expect continued strength through 2025. It has a compelling efficacy profile supported by the CROWN study where the median progression free survival was not reached after 5 years of follow-up. LORBRENA is emerging as a standard of care for patients with first-line ALK positive metastatic non-small cell lung cancer. We saw continued momentum with Braftovi and Mektovi with 23% year-over-year operational growth in the second quarter. Result for the Phase III BREAKWATER trial showed the Braftovi combination regimen doubled median overall survival versus standard of care for treatment-naive patients with metastatic colorectal cancer with BRAF V600E mutation. This represents a significant advancement of the approximately 4,000 patients diagnosed annually in the U.S. with metastatic colorectal cancer with this mutation. They face a mo”